Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 1000 mg

Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 500 mg

Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 2+0,25 g

Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 4+0,5 g

Europäische Union - Dänisch - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.